Hongliang Zong

TL;DR: In this article, the authors report the development of highly potent and orally bioavailable small-molecule inhibitors of the menin-MLL interaction, MI-463 and MI-503, and show their profound effects in mixed lineage leukemia cells and substantial survival benefit in mouse models of MLL leukemia.

TL;DR: This work uses PU-H71 affinity capture to design a proteomic approach that, when combined with bioinformatic pathway analysis, identifies dysregulated signaling networks and key oncoproteins in chronic myeloid leukemia and shows that this method can provide global insights into the biology of individual tumors, including primary patient specimens.

TL;DR: It is found that under conditions of stress, such as malignant transformation fuelled by MYC, the chaperome becomes biochemically ‘rewired’ to form a network of stable, survival-facilitating, high-molecular-weight complexes.

TL;DR: Administration of the clinically approved iron oxide nanoparticle drug ferumoxytol in vitro results in an anti-leukaemia effect and in vivo extended overall survival in part due to the low expression of the iron export protein ferroportin.

TL;DR: The development of a protein-protein interaction inhibitor, AI-10-49, that selectively binds to CBFβ-SMMHC and disrupts its binding to RUNX1 is reported, suggesting that direct inhibition of the oncogenic CBF β-sMMHC fusion protein may be an effective therapeutic approach for inv(16) AML and they provide support for transcription factor targeted therapy in other cancers.